Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Rev. esp. med. nucl. (Ed. impr.) ; 24(2): 113-126, mar.-abr. 2005. ilus, tab, graf
Article in Es | IBECS | ID: ibc-037384

ABSTRACT

Objetivo: La detección de la recurrencia secundaria a cáncer de ovario es un problema de importancia notoria, pudiendo mediante un diagnóstico correcto ofrecer alternativas útiles en el manejo de las pacientes. El objetivo de este estudio ha sido valorar el impacto terapéutico de la PET-FDG en la recurrencia por cáncer de ovario. Material y métodos: Se han incluido 43 enfermas con cáncer de ovario en las que se efectuó el estudio PET-FDG ante la sospecha diagnóstica de recidiva. Los resultados de la PET-FDG se confirmaron por histopatología y seguimiento clínico mayor de 12 meses. Se ha comparado el impacto en el manejo de las pacientes basado en los métodos convencionales de imagen, con el plan de tratamiento considerando los hallazgos de la PET-FDG, clasificando el impacto de la PET-FDG como alto, medio, bajo o no impacto. Los cambios en el manejo terapéutico de las enfermas, han sido clasificados como intermodalidad o intramodalidad. Resultados: El estudio PET-FDG obtuvo un impacto alto en el manejo terapéutico de 28 pacientes (65,1 %), un impacto medio en 2 pacientes (4,6 %), un impacto bajo en 9 pacientes (20,9 %), y no tuvo impacto en 4 enfermas (9,3 %). La PET-FDG indujo un cambio intermodalidad en 27 pacientes (62,8 %); un cambio intramodalidad en 3 pacientes (7 %); y finalmente en 13 enfermas (30,2 %), no produjo ningún cambio en el tratamiento. Conclusiones: La PET-FDG proporciona una información adicional con respecto a los métodos diagnósticos de imagen convencional, permitiendo efectuar cambios en el manejo terapéutico en la mayoría de las enfermas


Aim: Recurrent ovarian cancer is a major problem and an accurate diagnosis can often change patients' management. This study aimed to assess the impact on management of FDG-PET in recurrent ovarian cancer. Material and methods: Forty-three patients in whom FDG-PET scan was performed due to suspected recurrent ovarian cancer were included. FDG-PET results were confirmed by histopathology and clinical follow-up of at least 12 months. To assess impact on management the treatment plan based on conventional imaging methods was compared with the treatment plan based on inclusion of PET findings, classifying FDG-PET impact on management as high, medium, low or no impact. Management changes, when present, were classified as intermodality or intramodality. Results: FDG-PET had a high impact on therapeutic management in 28 patients (65.1 %), medium impact in 2 patients (4.6 %), low impact in 9 patients (20.9 %), and no impact in 4 patients (9.3 %). FDG-PET induced an intermodality change in management in 27 patients (62,8 %); intramodality changes were induced in 3 patients (7 %). Finally, it produced no treatment changes in 13 patients (30.2 %). Conclusion: FDG-PET supplied additional information when compared to conventional diagnostic procedures and allowed adequate management changes in most patients


Subject(s)
Female , Adult , Aged , Humans , Tomography, Emission-Computed , Radiopharmaceuticals , Fluorodeoxyglucose F18 , Neoplasm Recurrence, Local , Ovarian Neoplasms , Ovarian Neoplasms/therapy , Retrospective Studies
2.
Rev Esp Med Nucl ; 24(2): 113-26, 2005.
Article in Spanish | MEDLINE | ID: mdl-15745682

ABSTRACT

AIM: Recurrent ovarian cancer is a major problem and an accurate diagnosis can often change patients' management. This study aimed to assess the impact on management of FDG-PET in recurrent ovarian cancer. MATERIAL AND METHODS: Forty-three patients in whom FDG-PET scan was performed due to suspected recurrent ovarian cancer were included. FDG-PET results were confirmed by histopathology and clinical follow-up of at least 12 months. To assess impact on management the treatment plan based on conventional imaging methods was compared with the treatment plan based on inclusion of PET findings, classifying FDG-PET impact on management as high, medium, low or no impact. Management changes, when present, were classified as intermodality or intramodality. RESULTS: FDG-PET had a high impact on therapeutic management in 28 patients (65.1 %), medium impact in 2 patients (4.6 %), low impact in 9 patients (20.9 %), and no impact in 4 patients (9.3 %). FDG-PET induced an intermodality change in management in 27 patients (62,8 %); intramodality changes were induced in 3 patients (7 %). Finally, it produced no treatment changes in 13 patients (30.2 %). CONCLUSION: FDG-PET supplied additional information when compared to conventional diagnostic procedures and allowed adequate management changes in most patients.


Subject(s)
Fluorodeoxyglucose F18 , Neoplasm Recurrence, Local/diagnostic imaging , Ovarian Neoplasms/diagnostic imaging , Ovarian Neoplasms/therapy , Positron-Emission Tomography , Radiopharmaceuticals , Adult , Aged , Female , Humans , Middle Aged , Retrospective Studies
3.
Health Phys ; 84(4): 451-6, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12705443

ABSTRACT

To develop a practical means of auditing the procedures and to optimize the administered radionuclide activity, patient surface radiation doses following the administration of 18FDG for PET imaging have been measured at breast and gonad locations at two PET facilities. Patient dosimetry was performed using LiF TLD-100 chips placed near the breasts and gonads for 2 h following tracer injection. Standard uptake values from the image-reconstruction algorithms of one PET camera were investigated in regions of interest in tomograms of the myocardium and liver with the aim of validating dosimetry at breasts. Mean doses measured on the patient's skin ranged between 3.3 and 6.1 microGy MBq(-1) at the gonads and between 3.9 and 6.4 microGy MBq(-1) at the breasts, noticeably lower than the calculations reported in the literature. These values show good concordance with the injected activities, although they are not proportional. The proportion of injected activity actually contributing to image production seems to decrease gradually as the injected activity increases. Conversely, for a given injected activity, breast and gonadal doses were found to be lower than the values expected from the numerical calculations reported in the literature, showing increasing discrepancies when the injected activity increased. Doses measured at the right breast were consistently higher than for the left, which is indicative of greater radiotracer absorption by the liver compared to the average absorption in the body.


Subject(s)
Breast/metabolism , Fluorodeoxyglucose F18/pharmacokinetics , Gonads/metabolism , Ovary/metabolism , Radiometry/methods , Skin/metabolism , Adult , Breast/diagnostic imaging , Female , Gonads/diagnostic imaging , Heart/diagnostic imaging , Humans , Liver/diagnostic imaging , Liver/metabolism , Male , Myocardium/metabolism , Organ Specificity , Radiation Dosage , Radiometry/instrumentation , Radionuclide Imaging , Radiopharmaceuticals , Reproducibility of Results , Safety , Sensitivity and Specificity , Thermoluminescent Dosimetry/instrumentation
4.
Rev Esp Med Nucl ; 21(6): 403-9, 2002.
Article in Spanish | MEDLINE | ID: mdl-12425887

ABSTRACT

OBJECTIVE: The objective of this work was to assess the Standardized Uptake Value (SUV) in the differential diagnosis of radiologically indeterminate lung lesions by means of ROC curves. MATERIAL AND METHOD: Forty seven patients were studied by Positron Emission Tomography with 18-fluorine-2-desoxy-D-glucose (FDG PET) analyzing the value of maximum SUV. The patients were classified into three groups. Group 1 = patients without previous neoplasia (WPN) + patients with previous neoplasia (PN). Group 2 = WPN. Group 3 = PN. RESULTS: The ROC curves showed a high diagnostic accuracy in the three groups, with area under the curve (AUC) values of 0.96, 0.98 and 0.91 respectively. The typical error was 0.03, 0.02 and 0.08. The maximum SUV cutoffs with the best diagnostic accuracy for the three groups were: 2.6; 3 and 2.4, with an accuracy (A) of 93.6%, 97% and 92.3%, respectively. Analyzing all the patients globally (group 1), we obtained one false positive result in a patient with hamartoma (max SUV = 2.8) and two false negative results in one patient with lung metastases from malignant fibrohistiocytoma (max SUV = 0.7) and in another patient with lung metastases from unknown origin adenocarcinoma (max SUV = 1.9). CONCLUSIONS: FDG PET permits differentiation with a very high diagnostic accuracy of benign and malignant lung lesions using the maximum SUV. The differences observed between the different groups are due to the different disease prevalence, obtaining a lower negative predictive value of max SUV in patients with previous neoplasia.


Subject(s)
ROC Curve , Solitary Pulmonary Nodule/diagnostic imaging , Tomography, Emission-Computed , Adult , Aged , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Small Cell/diagnostic imaging , Diagnosis, Differential , Female , Fluorodeoxyglucose F18 , Hamartoma/diagnostic imaging , Humans , Lipoma/diagnostic imaging , Lung Diseases/diagnostic imaging , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/secondary , Male , Middle Aged , Pneumonia/diagnostic imaging , Predictive Value of Tests , Radiography , Radiopharmaceuticals , Tomography, Emission-Computed/statistics & numerical data , Tuberculoma/diagnostic imaging
5.
Rev. esp. med. nucl. (Ed. impr.) ; 21(6): 403-409, nov. 2002.
Article in Es | IBECS | ID: ibc-17457

ABSTRACT

Objetivo: El objetivo de este trabajo ha sido estudiar el valor del 'Standardized Uptake Value' (SUV) en el diagnóstico diferencial de lesiones pulmonares radiológicamente indeterminadas mediante CURVAS ROC. Material y método: Se han estudiado mediante tomografía por emisión de positrones con 18-fluoro-2-desoxi-Dglucosa (PET- FDG) un total de 47 pacientes analizando el valor del SUV máximo. Los enfermos han sido agrupados de la siguiente forma: grupo 1 = pacientes sin antecedentes de neoplasia (PSAN) + pacientes con antecedentes de neoplasia (PCAN); grupo 2 = PSAN; grupo 3 = PCAN. Resultados: En los tres grupos analizados las CURVAS ROC muestran unos valores del Área Bajo la Curva (ABC) para los grupos 1, 2 y 3, de: 0,96, 0,98 y 0,91. Los puntos de corte de mayor exactitud diagnóstica fueron para el grupo 1, 2, y 3 de: 2,6; 3 y 2,4, con una exactitud diagnóstica (ED) del 93,6 per cent, 97 per cent y 92,3 per cent, respectivamente. Analizando globalmente todos los pacientes (grupo 1), sólo hemos obtenido un resultado falso positivo en un paciente con un hamartoma (SUV de 2,8) y dos resultados falsos negativos en dos casos de metástasis pulmonares secundarias a: fibrohistiocitoma maligno (SUV 0,7) y adenocarcinoma de origen desconocido (SUV 1,9). Conclusiones: La FDG-PET permite diferenciar lesiones pulmonares benignas de malignas mediante la obtención del SUV con una elevada exactitud diagnóstica. Las diferencias observadas entre los grupos analizados se atribuyen a la diferente prevalencia de enfermedad, identificándose en los enfermos con antecedentes de neoplasia primaria un menor valor predictivo negativo del SUV (AU)


Subject(s)
Middle Aged , Aged , Adult , Male , Female , Humans , ROC Curve , Tomography, Emission-Computed , Tuberculoma , Radiopharmaceuticals , Pneumonia , Solitary Pulmonary Nodule , Diagnosis, Differential , Lipoma , Hamartoma , Carcinoma, Small Cell , Predictive Value of Tests , Fluorodeoxyglucose F18 , Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Lung Diseases , Fluorodeoxyglucose F18
6.
Q J Nucl Med ; 46(2): 113-21, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12114874

ABSTRACT

BACKGROUND: The aim of this work is to assess the diagnostic value of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG), in the early detection of tumour recurrence in already treated breast cancer patients in apparent complete remission and with a progressive elevation of tumour markers CEA and/or CA 15.3 without any other clinical or instrumental signs of relapses. METHODS: The author studied 45 women (mean age 58+/-12, range 35-80 years) with histological diagnosis of breast cancer who underwent a tumour marker-guided whole body FDG-PET. All patients were in remission, without any other clinical or instrumental signs of relapses, except for the progressive elevation of CA 15.3 and/or CEA, tested during the follow-up. FDG-PET results were controlled by pathology when histological sampling was possible, by other conventional imaging modalities (US, X-rays, CT, MRI) and/or by clinical follow-up up to 12 months at least. RESULTS: FDG-PET findings were evaluated in 38 patients: 27 resulted positive. Among these 27 PET positive patients 24 were true positive and 3 false positive. Tumour marker guided FDG-PET was also able to discover 3 unknown neoplasms not visualized by other modalities. PET revealed 54 sites of intense focal FDG uptake. The anatomical distribution of these sites was 19 skeleton, 18 lymph node basins, 5 liver, 5 pelvic region, 1 lung, 1 pericardium, 1 pleura, 1 contralateral breast, 2 peritoneum and 1 thyroid bed. Forty-eight of these 54 sites of FDG accumulation were confirmed to be metastases. FDG-PET resulted negative in 11 patients and only in 2 of them the other diagnostic modalities were able to discover metastatic lesions; we had 9 true negative and 2 false positive RESULTS. On the basis of our investigation the performances of tumour marker guided FDG-PET per patient are as follows: sensitivity 92% (24/26), specificity 75% (9/12), positive predictive value 89% (24/27), negative predictive value 82% (9/11), accuracy 87% (33/38). CONCLUSIONS: This study demonstrated the clinical utility of tumour marker-guided PET in the follow-up of breast cancer patients. This diagnostic approach allowed to modify the clinical management in those patients in whom a tumor relapse or unexpected primary neoplasm was discovered.


Subject(s)
Breast Neoplasms/diagnostic imaging , Fluorodeoxyglucose F18 , Neoplasm Recurrence, Local/diagnostic imaging , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Breast Neoplasms/diagnosis , Carcinoembryonic Antigen/blood , False Positive Reactions , Follow-Up Studies , Humans , Middle Aged , Mucin-1/blood , Neoplasm Recurrence, Local/diagnosis , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity , Tomography, Emission-Computed
8.
Rev Neurol ; 30(4): 359-63, 2000.
Article in Spanish | MEDLINE | ID: mdl-10789147

ABSTRACT

INTRODUCTION: The incorporation of neuroimaging techniques into the protocol for localization of epileptogenous foci has considerably reduced the need for use of intracranial electrodes. DEVELOPMENT: SPECT and PET are most useful in cases of epilepsy with no cerebral morphological anomalies, in which there are therefore no changes which shown on MR. Cerebral SPECT with perfused tracers, such as 99mTc-HMPAO, 123I-MP or 99mTc-ECD, permit the study of patients during interictal and perictal phases. In the latter case, although the procedure is complex, one may observe an increase in cerebral blood flow in the epileptogenous focus in 90% of the patients. PET with FDG allows interictal study of patients, and shows reduced metabolism in the epileptogenic region. By comparison with video-EEG there are S = 84% and SP = 86% in temporal lobe epilepsy. The diagnostic efficiency of these two techniques is rather less in the localization of extratemporal foci and in multifocal epilepsies, although it is always better than with other diagnostic techniques. They have also been shown to be useful in the prognosis of functional recovery after surgery. CONCLUSION: The possibility of studying neuroreceptors may be of great use in the investigation of the etiopathogenesis of epilepsy, and thus lead to improvement in the clinical and therapeutic management of patients. With SPECT, 123I-Iomacenil and 123I-lododexetimide are used. With PET and 11C-Carfentanyl opiate receptors have been studied. With 11C-Fluomacenil one may study the cerebral distribution of the benzodiazepine receptors.


Subject(s)
Epilepsy/diagnostic imaging , Tomography, Emission-Computed, Single-Photon , Tomography, Emission-Computed , Brain/blood supply , Brain/metabolism , Contrast Media , Humans , Radiopharmaceuticals
9.
Rev. neurol. (Ed. impr.) ; 30(4): 359-363, 16 feb., 2000.
Article in Es | IBECS | ID: ibc-20435

ABSTRACT

Introducción. La incorporación de las técnicas de neuroimagen al protocolo de localización de los focos epileptógenos ha disminuido de forma considerable la necesidad de utilizar electrodos intracraneales. Desarrollo. La SPECT y PET alcanzan su máxima utilidad en aquellos casos en que las epilepsias no cursan con anomalías morfológicas cerebrales y que, por tanto, no son visibles con RM. La SPECT cerebral con trazadores de perfusión, como 99m Tc-HMPAO, 123 I-IMP o 99m Tc-ECD, permite estudiar a los pacientes en fase interictal y perictal; en este último caso, aunque la metodología es complicada, se puede observar aumento de flujo sanguíneo cerebral en el foco epileptógeno en un 90 por ciento de los pacientes. La PET con FDG permite el estudio interictal de los pacientes, demostrando disminución del metabolismo en la región epileptógena. En comparación con el vídeo-EEG presenta una S= 84 por ciento yE= 86 por ciento en las epilepsias del lóbulo temporal. El rendimiento diagnóstico de ambas técnicas es algo menor en la localización de focos extratemporales y de epilepsias multifocales, aunque siempre mayorque con otras técnicas diagnósticas. También han demostrado tener valor pronóstico en el examen de la recuperación funcional tras la cirugía. Conclusiones. La posibilidad de estudiar neurorreceptorespuede ser de gran utilidad en la investigación de la etiopatogenia de la epilepsia, condicionando así un mejor manejo clínico y terapéutico de los pacientes. Con la SPECT se utiliza el 123 I-Iomacenil y la123 I-Iododexetimida.Con la PET y el 11C-Carfentanilse han estudiado los receptores opiáceos. Con el 11C-Fluomacenil puede estudiarse la distribución cerebral de los receptores benzodiacepínicos (AU)


Subject(s)
Humans , Tomography, Emission-Computed , Tomography, Emission-Computed, Single-Photon , Radiopharmaceuticals , Contrast Media , Epilepsy , Telencephalon
10.
Clin Nucl Med ; 18(1): 19-21, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8422714

ABSTRACT

An esophagobronchial fistula developed in a patient who had well-differentiated squamous carcinoma of the lung that was treated with chemotherapy. Because the esophagobronchial fistula could not be surgically repaired, it was isolated with a mechanical stitch above and below it. Forty-eight hours after initiation of enteral nutrition, a perfusion lung scan was performed because of clinical suspicion of pulmonary embolism. Because the scan showed reduced pulmonary radioactivity and accumulation of activity in the kidneys and spine, an arteriovenous shunt was suspected. However, subsequent digital subtraction angiography ruled out this possibility and a recurrence of the esophagobronchial fistula was confirmed with an esophagogram. The unusual extrapulmonary activity could be related to a reversible capillary shunt in the pulmonary vasculature, secondary to acute respiratory distress syndrome.


Subject(s)
Lung/diagnostic imaging , Respiratory Distress Syndrome/diagnostic imaging , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bronchial Fistula/complications , Carcinoma, Squamous Cell/drug therapy , Esophageal Fistula/complications , Humans , Lung Neoplasms/drug therapy , Male , Middle Aged , Pneumonia, Aspiration/complications , Radionuclide Imaging , Recurrence , Respiratory Distress Syndrome/etiology , Technetium Tc 99m Aggregated Albumin
11.
Rev Esp Enferm Dig ; 80(3): 173-7, 1991 Sep.
Article in Spanish | MEDLINE | ID: mdl-1836331

ABSTRACT

By means of ultrasonography it is possible to detect hepatic lesions of few millimeters, however, it doesn't give a precise diagnosis. The role of planar scintigraphy in the diagnosis of hepatic hemangioma has already been established, although it has limitations which are partially solved by means of SPECT. 46 patients with different pathologies and 9 healthy volunteers have been studied. In the 19 confirmed hemangiomas, planar scintigraphy showed a sensitivity of 73.6% versus 84.2% for SPECT, mostly due to lesions less than 2.5 cm. Besides that, SPECT allowed a correct visualization of abdominal and intrahepatic major vessels, although lesions less than 1.5 cm are difficult to evaluate.


Subject(s)
Hemangioma/diagnostic imaging , Liver Neoplasms/diagnostic imaging , Tomography, Emission-Computed, Single-Photon , Adult , Aged , Erythrocytes/diagnostic imaging , Female , Humans , Liver/diagnostic imaging , Male , Middle Aged , Scintillation Counting , Technetium Tc 99m Pyrophosphate
13.
J Heart Lung Transplant ; 10(1 Pt 1): 33-7, 1991.
Article in English | MEDLINE | ID: mdl-2007169

ABSTRACT

An original index has been derived from thallium images to detect histopathologic changes in heart transplant patients. One hundred eighty-four static and end-diastolic images with thallium were recorded 5 minutes after injection in the left anterior oblique projection. Twenty patients and 14 healthy volunteers were studied. The epicardial and endocardial borders were determined, and the difference of these values was considered the myocardial area. The results in heart transplants were compared with the results of endomyocardial biopsies (N = 142). A significant decrease (p less than 0.01) was found in the index of the myocardial area between normal biopsy results and mild and moderate rejection. Differences were not detected between studies performed in several postoperative periods in the absence of rejection. The results in healthy volunteers prove that the index does not change between studies performed at different times in the same subject, although the value obtained from the end-diastolic image was more constant. On the basis of these results, it is possible to suggest that the decrease in the myocardial area during rejection is the result of a fall of thallium uptake by the myocardium. Capillary endothelial hyperplasia, perivascular infiltration, and myocytolysis can justify these changes, although the presence of other histologic findings, such as intramyocardial edema, could influence the value of this index. We conclude that the uptake of thallium decreases during acute rejection episodes; the results obtained from the images, in this work, are an expression of this event.


Subject(s)
Graft Rejection , Heart Transplantation/pathology , Heart/diagnostic imaging , Myocardium/pathology , Thallium Radioisotopes , Adult , Biopsy , Evaluation Studies as Topic , Humans , Immunosuppressive Agents/therapeutic use , Radionuclide Imaging
14.
Med Clin (Barc) ; 96(1): 1-5, 1991 Jan 12.
Article in Spanish | MEDLINE | ID: mdl-2023461

ABSTRACT

Brain single photon emission computed tomography (SPECT) with 99mTc-HMPAO is a diagnostic tool for evaluating regional cerebral blood flow. Recently, the diagnostic possibilities of the method are being investigated in some neurologic disorders, such as cerebrovascular accidents, seizures and dementia. This work has been carried out with 54 subjects, 9 healthy volunteers and 45 patients (31 dementia and 14 epileptics), in order to evaluate gammagraphic patterns and the utility of cortico/cerebellar activity indexes. An interesting diagnostic finding is a significant decrease (p less than 0.001) in perfusion of temporoparietal regions in the patients with Alzheimer's disease in relation with the healthy volunteers' group. We have not found significant changes in perfusion in the group of epileptic patients during the interictal phase. We conclude emphasizing the interest of the SPECT in the differential diagnosis of dementia.


Subject(s)
Alzheimer Disease/diagnostic imaging , Brain/diagnostic imaging , Dementia/diagnostic imaging , Epilepsy/diagnostic imaging , Tomography, Emission-Computed, Single-Photon , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Gamma Rays , Humans , Middle Aged
15.
Eur J Nucl Med ; 16(3): 167-71, 1990.
Article in English | MEDLINE | ID: mdl-2364960

ABSTRACT

A semi quantitative method with thallium has been applied in the management of cardiac transplants. In all, 142 scans were performed in 20 patients and were arranged in 3 groups that represent respectively all controls performed to the transplants (G1), and a selection of the scans obtained during the 1st rejection episode in each patient (G2) and the 2nd if present (G3). A heart/lung index was calculated through early and late images (IA, IB), obtained 5 min and 4 h post injection of thallium. A decrease in IA was detected during acute rejection in all groups. This fall was statistically significant from the mild to moderate rejection degree in G1 (P less than 0.01), and the mild rejection in G3 (P less than 0.001). IB was not modified with rejection. Comparing the biopsies with and without edema, in the absence of rejection, it has been proved that the intra myocardial edema can produce a decrease in IA (P less than 0.001). We conclude that IA is a simple and sensitive index to evaluate the graft, although intra myocardial edema can reduce its specificity.


Subject(s)
Coronary Circulation , Graft Rejection/physiology , Heart Transplantation/physiology , Heart/diagnostic imaging , Thallium Radioisotopes , Heart/physiology , Humans , Radionuclide Imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...